ClinicalTrials.gg

Program

Akt-1 Antisense Oligonucleotide WGI-0301

Also written as “WGI-0301”, “WGI-0301 at MTD/RP2D dose IV infusion, QW” and “WGI-0301 at MTD/RP2D -1 dose IV infusion, QW”.

Its studies are mostly in Carcinoma, Hepatocellular · Carcinoma, Renal Cell, led by Zhejiang Haichang Biotech.

Furthest: phase 2, since Mar 1, 20244 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Zhejiang Haichang Biotech44 open or runningphase 2since Mar 1, 2024Feb 8, 2022Dec 2026phase 2 · NCT06309485

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 8, 2022First study: phase 1 study in Advanced Solid TumorsFirst studyNCT05267899 · 24 planned · United States
  2. Mar 1, 2024Phase 2 study in Advanced Hepatocellular Carcinoma (HCC)NCT06309485 · 60 planned · China, Hong Kong
  3. Mar 16, 2026Phase 2 study in Carcinoma, Renal CellNCT07494435 · 230 planned · China
  4. Apr 14, 2026Phase 2 study in Advanced Hepatocellular Carcinoma (HCC)NCT07540832 · 80 planned · United States

Ahead

  1. Dec 2026Primary completion: phase 2 study in Advanced Hepatocellular Carcinoma (HCC)NCT06309485
  2. Jun 1, 2028Primary completion: phase 2 study in Carcinoma, Renal CellNCT07494435
  3. Sep 2028Primary completion: phase 2 study in Advanced Hepatocellular Carcinoma (HCC)NCT07540832

TargetBeta

HLA-B →read by rule
“A lipid nanoparticle preparation of archexin, a 20-mer antisense (AS) oligodeoxynucleotide (ODN) against the proto-oncogene Akt, ”NCIt, by rule

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07540832Advanced Hepatocellular Carcinoma (HCC) · United States2Not yet recruitingSep 202880
NCT07494435Carcinoma, Renal Cell · China2Not yet recruitingJun 1, 2028230
NCT06309485Advanced Hepatocellular Carcinoma (HCC) · China, Hong Kong2RecruitingDec 202660
NCT05267899Advanced Solid Tumors · United States1RecruitingOct 15, 202424

How it is read

Names in the registry

  • “WGI-0301”, 5 entries
  • “WGI-0301 at MTD/RP2D dose IV infusion, QW”, 1 entry
  • “WGI-0301 at MTD/RP2D -1 dose IV infusion, QW”, 1 entry

Codes read as this program: WGI0301.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.